We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current SHTDY market cap is 8.54B. The company's latest EPS is CNY 14.5062 and P/E is 0.19.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 425.27B | 456.41B | 521.05B | 552.15B | 596.57B |
| Operating Income | 19.21B | 20.51B | 21.9B | 24.22B | 24B |
| Net Income | 6.25B | 7.19B | 7.76B | 8.53B | 9.05B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 269.89B | 311.24B | 335.41B | 364.78B | 383.39B |
| Total Liabilities | 192.95B | 221.29B | 235.76B | 254.71B | 263.08B |
| Total Equity | 76.94B | 89.95B | 99.65B | 110.07B | 120.32B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 18.78B | 11.15B | 9.31B | 20.96B | 17.17B |
| Investing | -6.8B | -2.2B | -1.27B | -3.59B | -944.54M |
| Financing | -13.08B | 2.03B | -14.69B | -5.69B | -7.64B |
| Market Cap | 8.54B |
| Price to Earnings Ratio | 0.19 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.03 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 624.13M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.55 (3.95%) |
| Company Name | Sinopharm Group Company Ltd (PK) |
| Address |
6th floor, no. 221 fuzhou road shanghai 200002 |
| Website | https://www.sinopharmgroup.com.cn |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
